New AI Partnership Targets Precision Autism Care Research
A new collaboration aims to use AI to help identify biomarkers for personalized autism care in children.
Updated on Oct. 15, 2026 in Autism
Live Poll
Would you trust AI-driven analysis of your medical data to improve your personalized healthcare outcomes?
Neumarker and Cortica have launched a partnership to use artificial intelligence and clinical data to research potential biomarkers for autism. The collaboration aims to identify biological markers that could eventually help personalize neurological therapies for children.
Why it matters
Currently, clinicians struggle to predict how individual children with autism will respond to different treatments due to the condition's wide clinical diversity. This research project seeks to address that gap by using large-scale brain intelligence models to guide more precise care strategies.
The collaboration leverages a clinical operational footprint of 20,000 patients served annually and 2,300 clinicians to power the research. Whether these combined datasets will yield predictive clinical biomarkers remains under investigation.
The players
Neumarker
A developer of AI-native brain intelligence platforms and EEG foundation models for central nervous system medicine.
Cortica
A healthcare provider founded in 2017 that offers neurological therapies for children with autism and developmental differences.
The details
The partnership integrates Neumarker's brain intelligence platform, which utilizes large-scale EEG foundation models, with Cortica's longitudinal clinical data. By analyzing this information, researchers aim to uncover distinct biological patterns that account for the variable responses children often have to neurological therapies. All research will utilize de-identified patient data to maintain privacy standards while training the AI to recognize complex neurological profiles.
Timeline
2017: Cortica was founded.
October 15, 2026: Neumarker and Cortica announced their strategic collaboration.
Health Landscape
This project aligns with the goals of the Precision Medicine Initiative by attempting to move autism care beyond generalized therapies. It represents a shift toward using large-scale machine learning to uncover the biological heterogeneity that has historically defined neurodevelopmental research.
This collaboration is currently in the research phase and will not immediately change clinical care for families in California. If you are managing autism care, continue to monitor progress through your pediatric neurologist, as biomarker-based tools are not yet available for diagnostic or treatment decisions.
The takeaway
The use of AI in autism research is an emerging field aimed at matching children with the most effective therapies for their unique profiles. Families should view these developments as early-stage research rather than immediate changes to standard care practices.
Further reading
For more on the current research landscape, see our guide to Autism.
Source note: This article includes information reported by The Manila times.
Live Poll
Would you trust AI-driven analysis of your medical data to improve your personalized healthcare outcomes?
